Global pharmaceutical company Lupin Limited has entered into a licensing and supply agreement with Galenicum Health, S.L.U. for finished formulations of injectable semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. The agreement has been executed through Lupin’s wholly owned subsidiary, Lupin Atlantis Holdings SA (LAHSA).
Under the terms of the agreement, Galenicum will be responsible for the development, manufacturing, and supply of injectable semaglutide, while Lupin will lead regulatory filings, approvals, commercialization, and distributionacross 23 international markets. These markets include Canada, multiple European countries, Southeast Asia, and Latin America.
The partnership strengthens Lupin’s strategy to expand its diabetes and obesity treatment portfolio beyond India, leveraging its established commercial infrastructure in key global regions. Semaglutide is considered a critical therapy amid the rising global prevalence of type 2 diabetes and obesity, both of which represent major public health challenges.
Semaglutide, a generic form of GLP-1 therapy, works by regulating blood glucose levels and suppressing appetite. It is widely prescribed for adults with type 2 diabetes in combination with diet and exercise and is also indicated for long-term weight management in adults with obesity or overweight conditions.
For Galenicum, the agreement supports its strategy to scale high-volume production of GLP-1 therapies globally. The company has made significant investments in its GLP-1 development pipeline to address increasing global demand and position itself as a key business-to-business supplier in the GLP-1 segment.
The collaboration is expected to improve global access to cost-effective semaglutide therapies while reinforcing both companies’ roles in addressing growing metabolic health needs worldwide.
